Pharming Group N.V. - ADR

Pharming Group N.V. - ADR represents the American Depositary Receipts of Pharming Group N.V., a Netherlands-based biopharmaceutical company specializing in the development and commercialization of therapeutic proteins. Its primary focus is on pioneering treatments for rare diseases, utilizing proprietary technology for the production of recombinant human proteins. The company made significant advancements with its primary product, RUCONEST®, which is used for the treatment of hereditary angioedema—a rare genetic disorder characterized by recurring episodes of severe swelling. Pharming Group's expertise lies in its innovative domestic animal production platform, emphasizing the use of transgenic rabbits to produce high-quality proteins for medical therapies. This unique production method positions Pharming within critical healthcare sectors tackling unmet medical needs. The listing of Pharming Group N.V. as an ADR allows U.S. investors to gain exposure to its innovative biopharmaceutical activities while diversifying their investment portfolios internationally. By bridging the European and American financial markets, Pharming's ADRs facilitate access to pioneering medical advancements, contributing significantly to the global healthcare landscape.